Belotero Intense (+) Lidocaine
Merz North America, Inc. · Decision date Aug 31, 2026
What did the FDA approve?
FDA records P250016/S004 as a supplement to PMA P250016, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 31, 2026.
FDA approval order statement
approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250016.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Aug 31, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P250016/S004
- Regulatory pathway
- PMA supplement
- Applicant
- Merz North America, Inc.
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Aug 31, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
- Applicant
- Merz North America, Inc.
- Product code
- LMH
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250016. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250016 · Original PMA
Belotero Intense (+) Lidocaine
P250016/S002 · Related supplement
Belotero Intense (+) Lidocaine
P250016/S004 received
Application receipt date recorded by FDA.
P250016/S001 · Related supplement
Belotero Intense (+) Lidocaine
P250016/S004 · FDA decision
Normal 180 Day Track No User Fee
P250016/S006 · Related supplement
Belotero Intense (+) Lidocaine Dermal Filler
Timeline entries are records held by MedtechLedger for P250016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Merz North America, Inc. | PMA approval | Jul 9, 2026 | FDA | |
Belotero Intense (+) LidocaineP250016/S002 | Merz North America, Inc. | PMA supplement | Jul 31, 2026 | FDA |
Belotero Intense (+) LidocaineP250016/S001 | Merz North America, Inc. | PMA supplement | Aug 5, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
saypha ChiQP250021/S001 | Croma-Pharma GmbH | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Merz North America, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6501 Six Forks Rd., Raleigh, NC, 27615
Sources and methodology
- Original FDA record: P250016/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





